Patents by Inventor Devin Leake

Devin Leake has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • siRNA Targeting Catenin, Beta-1 (CTNNB1)
    Publication number: 20140228251
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for CTNNB1.
    Type: Application
    Filed: February 12, 2013
    Publication date: August 14, 2014
    Applicant: DHARMACON, INC.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • Methods and Compositions for Selecting siRNA of Improved Functionality
    Publication number: 20140148362
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for TTR.
    Type: Application
    Filed: December 5, 2013
    Publication date: May 29, 2014
    Applicant: Thermo Fisher Scientific Biosciences Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • siRNA Targeting TIE-2
    Publication number: 20140094390
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed.
    Type: Application
    Filed: December 6, 2013
    Publication date: April 3, 2014
    Applicant: Thermo Fisher Scientific Biosciences Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • Modulators of Protein Production in a Human Cell Line and Cell-free Extracts Produced Therefrom
    Publication number: 20140066595
    Abstract: Cell-free extracts, methods for producing these extracts, methods for using these extracts, compositions that facilitate production of these extracts and kits that contain these extracts are provided. By increasing or decreasing certain gene products through, for example, the use of siRNA or mimics, one can develop mammalian cell-free extracts that have desired levels of efficiency.
    Type: Application
    Filed: August 26, 2013
    Publication date: March 6, 2014
    Applicant: THERMO FISHER SCIENTIFIC BIOSCIENCES INC.
    Inventors: Emily Anderson, Peter Bell, Penny Jensen, Jon Karpilow, Anja Smith, Krishna Vattem, Brian Webb, Devin Leake, Alex Medford, Elena Maksimova, Craig Smith
  • siRNA targeting tie-2
    Patent number: 8658785
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed.
    Type: Grant
    Filed: October 9, 2012
    Date of Patent: February 25, 2014
    Assignee: Thermo Fisher Scientific Biosciences Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read
  • siRNA targeting amyloid beta (A4) precursor protein (APP)
    Patent number: 8658784
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for APP.
    Type: Grant
    Filed: July 18, 2012
    Date of Patent: February 25, 2014
    Assignee: Thermo Fisher Scientific Biosciences Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • SiRNA targeting histamine receptor H1
    Patent number: 8633306
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed.
    Type: Grant
    Filed: August 10, 2011
    Date of Patent: January 21, 2014
    Assignee: Thermo Fisher Scientific Biosciences Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • Methods of modulating mesenchymal stem cell differentiation
    Patent number: 8580757
    Abstract: The present disclosure includes compositions and methods for modulating the differentiation of cells having osteogenic differentiation potential (such as mesenchymal stem cells (MSCs)) towards the osteogenic fate, and for obtaining diagnostic and prognostic information relating to diseases and disorders characterized by defects in osteogenic differentiation. The compositions include miRNAs, rm?RNA mimics, miRNA inhibitors, and siRNAs.
    Type: Grant
    Filed: August 7, 2008
    Date of Patent: November 12, 2013
    Assignee: Thermo Fisher Scientific Biosciences Inc.
    Inventors: Yuriy Federov, Devin Leake
  • siRNA targeting kinase insert domain receptor (KDR)
    Patent number: 8575329
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for KDR.
    Type: Grant
    Filed: June 15, 2012
    Date of Patent: November 5, 2013
    Assignee: Thermo Fisher Scientific Biosciences Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • siRNA Targeting Cyclin-dependent Kinase Inhibitor 1B (p27, Kip1) (CDKN1B)
    Publication number: 20130225667
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for CDKN1B.
    Type: Application
    Filed: April 22, 2013
    Publication date: August 29, 2013
    Applicant: DHARMACON, INC.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • siRNA Targeting Apolipoprotein B (APOB)
    Publication number: 20130225447
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for APOB.
    Type: Application
    Filed: April 22, 2013
    Publication date: August 29, 2013
    Applicant: DHARMACON, INC.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • siRNA Targeting Myeloid Differentiation Primary Response Gene (88) (MYD88)
    Publication number: 20130210676
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for MYD88.
    Type: Application
    Filed: March 20, 2013
    Publication date: August 15, 2013
    Applicant: DHARMACON, INC.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • Duplex oligonucleotide complexes and methods for gene silencing by RNA interference
    Patent number: 8501706
    Abstract: Provided herein are duplex oligonucleotide complexes which can be administered to a cell, tissue or organism to silence a target gene without the aid of a transfection reagent(s). The duplex oligonucleotide complexes of the disclosure include a conjugate moiety that facilitates delivery to a cell, tissue or organism.
    Type: Grant
    Filed: July 19, 2012
    Date of Patent: August 6, 2013
    Assignee: Dharmacon, Inc.
    Inventors: Christina Yamada, Anastasia Khvorova, Rob Kaiser, Emily Anderson, Devin Leake
  • SiRNA targeting connective tissue growth factor (CTGF)
    Patent number: 8461326
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to CTGF.
    Type: Grant
    Filed: February 14, 2012
    Date of Patent: June 11, 2013
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • SiRNA targeting apolipoprotein (APOB)
    Patent number: 8445668
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for APOB.
    Type: Grant
    Filed: June 28, 2012
    Date of Patent: May 21, 2013
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • SiRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B)
    Patent number: 8445667
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for CDKN1B.
    Type: Grant
    Filed: June 25, 2012
    Date of Patent: May 21, 2013
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • SiRNA targeting myeloid differentiation primary response gene (88) (MYD88)
    Patent number: 8426579
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for MYD88.
    Type: Grant
    Filed: August 11, 2011
    Date of Patent: April 23, 2013
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • Duplex oligonucleotides with enhanced functionality in gene regulation
    Patent number: 8415466
    Abstract: Disclosed are methods of enhancing functionality of duplex oligonucleotides and compositions made by the methods. The duplex oligonucleotides include siRNAs, miRNA mimics, and piRNA mimics which contain modified nucleotides and mismatches between the two strands of the molecule at specific nucleotide positions.
    Type: Grant
    Filed: April 30, 2012
    Date of Patent: April 9, 2013
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Devin Leake, Barbara Robertson, Annaleen Vermeulen, Christina Yamada
  • siRNA targeting catenin, Beat-1 (CTNNB1)
    Patent number: 8399654
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for CTNNB1.
    Type: Grant
    Filed: May 8, 2012
    Date of Patent: March 19, 2013
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • siRNA Targeting Fructose-1, 6-bisphosphatase 1 (FBP1)
    Publication number: 20130059760
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for FBP1.
    Type: Application
    Filed: October 1, 2012
    Publication date: March 7, 2013
    Applicant: DHARMACON, INC.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe